{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:57:27Z","timestamp":1762145847292,"version":"3.40.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009727","name":"Hospital Research Foundation","doi-asserted-by":"publisher","award":["#2021\/81-QA25313"],"award-info":[{"award-number":["#2021\/81-QA25313"]}],"id":[{"id":"10.13039\/100009727","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2033529"],"award-info":[{"award-number":["2033529"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The composition of the gut microbiota both prior to and after haematopoietic stem cell transplantation (HSCT) is increasingly implicated in the outcomes of HSCT, including infections, poor immune reconstitution and disease relapse. Faecal microbiota transplantation (FMT) offers a potential strategy of supporting the gut microbiota and improve HSCT outcomes. Although FMT has been investigated in HSCT recipients, it has largely been evaluated therapeutically for indications such as infection, or once immunocompetency is regained.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Peri-HSCT FMT (i.e. before and after HSCT) will be administered to eligible participants (adults undergoing autologous HSCT for a haematological malignancy) over two courses, with the first delivered immediately prior to conditioning and the second starting when ANC\u2009&gt;\u20090.8. Following an open-label, safety run in (N\u2009=\u20095), peri-HSCT FMT will be evaluated for its efficacy in 51 participants, randomised 2:1 to FMT or placebo. The primary outcome is the proportion of participants who develop severe gastrointestinal toxicity defined by 3 consecutive days of severe diarrhoea (Bristol Stool Chart 6+), at a frequency of 4\u2009+\u2009bowel movements\/day within 3 weeks of HSCT. Safety is defined as the incidence of treatment-emergent adverse events (TE-AEs). Tolerability is defined as the incidence of TE-AEs and adherence to FMT.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>The HSCT-BIOME study is a multi-centre, double-blind, randomised placebo-controlled trial designed to determine the tolerability, safety and efficacy of orally-administered encapsulated FMT to promote the stability of the gastrointestinal microenvironment for HSCT recipients. Peri-HSCT delivered FMT is hypothesised to promote microbial composition both before and following HSCT. Thus, the study will determine if administration of FMT post-HSCT during the neutropenic phase will enhance efficacy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>ACTRN12624001104549. Date of registration: September 19, 2024 (prospectively registered).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12885-025-14057-4","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T08:11:50Z","timestamp":1744272710000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A study protocol for a double-blinded, randomised, placebo-controlled trial on the use of encapsulated FMT for reducing the side effects of HSCT: the HSCT-BIOME study"],"prefix":"10.1186","volume":"25","author":[{"given":"Anna","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sam P.","family":"Costello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert V.","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Haylock-Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Haifer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Yeung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratyush","family":"Giri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle","family":"Blunt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne B.","family":"Bowen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feargal J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelina","family":"Yong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah R.","family":"Wardill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"issue":"5","key":"14057_CR1","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1111\/apt.12878","volume":"40","author":"Y Touchefeu","year":"2014","unstructured":"Touchefeu Y, Montassier E, Nieman K, et al. Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced Gastrointestinal mucositis - current evidence and potential clinical applications. Aliment Pharmacol Ther. 2014;40(5):409\u201321. https:\/\/doi.org\/10.1111\/apt.12878. [published Online First: 2014\/07\/22].","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"14057_CR2","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/bmt.2012.124","volume":"48","author":"BS van der Meij","year":"2013","unstructured":"van der Meij BS, de Graaf P, Wierdsma NJ, et al. Nutritional support in patients with GVHD of the digestive tract: state of the Art. Bone Marrow Transpl. 2013;48(4):474\u201382. https:\/\/doi.org\/10.1038\/bmt.2012.124. [published Online First: 2012\/07\/10].","journal-title":"Bone Marrow Transpl"},{"issue":"9674","key":"14057_CR3","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/s0140-6736(09)60237-3","volume":"373","author":"JL Ferrara","year":"2009","unstructured":"Ferrara JL, Levine JE, Reddy P, et al. Graft-versus-host disease. Lancet. 2009;373(9674):1550\u201361. https:\/\/doi.org\/10.1016\/s0140-6736(09)60237-3. [published Online First: 2009\/03\/14].","journal-title":"Lancet"},{"issue":"1","key":"14057_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s13073-016-0301-4","volume":"8","author":"E Montassier","year":"2016","unstructured":"Montassier E, Al-Ghalith GA, Ward T, et al. Pretreatment gut Microbiome predicts chemotherapy-related bloodstream infection. Genome Med. 2016;8(1):49. https:\/\/doi.org\/10.1186\/s13073-016-0301-4. [published Online First: 20160428].","journal-title":"Genome Med"},{"issue":"4","key":"14057_CR5","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1164\/rccm.201507-1491OC","volume":"194","author":"B Harris","year":"2016","unstructured":"Harris B, Morjaria SM, Littmann ER, et al. Gut microbiota predict pulmonary infiltrates after allogeneic hematopoietic cell transplantation. Am J Respir Crit Care Med. 2016;194(4):450\u201363. https:\/\/doi.org\/10.1164\/rccm.201507-1491OC.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"14057_CR6","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/nrc.2018.10","volume":"18","author":"Y Shono","year":"2018","unstructured":"Shono Y, van den Brink MRM. Gut microbiota injury in allogeneic Haematopoietic stem cell transplantation. Nat Rev Cancer. 2018;18(5):283\u201395. https:\/\/doi.org\/10.1038\/nrc.2018.10. [published Online First: 2018\/02\/17].","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"14057_CR7","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1136\/gutjnl-2016-313017","volume":"66","author":"G Cammarota","year":"2017","unstructured":"Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut. 2017;66(4):569\u201380. https:\/\/doi.org\/10.1136\/gutjnl-2016-313017. [published Online First: 2017\/01\/15].","journal-title":"Gut"},{"issue":"16","key":"14057_CR8","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1182\/blood-2016-05-717652","volume":"128","author":"K Kakihana","year":"2016","unstructured":"Kakihana K, Fujioka Y, Suda W, et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood. 2016;128(16):2083\u201388. https:\/\/doi.org\/10.1182\/blood-2016-05-717652. [published Online First: 20160726].","journal-title":"Blood"},{"issue":"10","key":"14057_CR9","doi-asserted-by":"publisher","first-page":"e776","DOI":"10.1016\/s2352-3026(22)00223-x","volume":"9","author":"F Malard","year":"2022","unstructured":"Malard F, Gaugler B, Mohty M. Faecal microbiota transplantation in patients with haematological malignancies undergoing cellular therapies: from translational research to routine clinical practice. Lancet Haematol. 2022;9(10):e776\u201385. https:\/\/doi.org\/10.1016\/s2352-3026(22)00223-x. [published Online First: 2022\/09\/30].","journal-title":"Lancet Haematol"},{"key":"14057_CR10","doi-asserted-by":"publisher","first-page":"103038","DOI":"10.1016\/j.jaut.2023.103038","volume":"141","author":"R Yang","year":"2023","unstructured":"Yang R, Chen Z, Cai J. Fecal microbiota transplantation: emerging applications in autoimmune diseases. J Autoimmun. 2023;141:103038. https:\/\/doi.org\/10.1016\/j.jaut.2023.103038. [published Online First: 20230426].","journal-title":"J Autoimmun"},{"issue":"34","key":"14057_CR11","doi-asserted-by":"publisher","first-page":"5306","DOI":"10.1200\/jco.22.02366","volume":"41","author":"A Rashidi","year":"2023","unstructured":"Rashidi A, Ebadi M, Rehman TU, et al. Randomized Double-Blind phase II trial of fecal microbiota transplantation versus placebo in allogeneic hematopoietic cell transplantation and AML. J Clin Oncol. 2023;41(34):5306\u201319. https:\/\/doi.org\/10.1200\/jco.22.02366. [published Online First: 20230526].","journal-title":"J Clin Oncol"},{"issue":"1","key":"14057_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s12916-016-0680-9","volume":"14","author":"I Youngster","year":"2016","unstructured":"Youngster I, Mahabamunuge J, Systrom HK, et al. Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent clostridium difficile infection. BMC Med. 2016;14(1):134. https:\/\/doi.org\/10.1186\/s12916-016-0680-9. [published Online First: 20160909].","journal-title":"BMC Med"},{"issue":"34","key":"14057_CR13","doi-asserted-by":"publisher","first-page":"5320","DOI":"10.1200\/jco.23.01169","volume":"41","author":"JU Peled","year":"2023","unstructured":"Peled JU, Brink MRM. Fecal transplantation in hematopoietic transplantation. J Clin Oncol. 2023;41(34):5320\u201323. https:\/\/doi.org\/10.1200\/jco.23.01169.","journal-title":"J Clin Oncol"},{"issue":"2","key":"14057_CR14","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1182\/bloodadvances.2021005110","volume":"6","author":"A Eshel","year":"2022","unstructured":"Eshel A, Sharon I, Nagler A, et al. Origins of bloodstream infections following fecal microbiota transplantation: a strain-level analysis. Blood Adv. 2022;6(2):568\u201373. https:\/\/doi.org\/10.1182\/bloodadvances.2021005110.","journal-title":"Blood Adv"},{"key":"14057_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.coph.2019.04.008","volume":"49","author":"FE Dailey","year":"2019","unstructured":"Dailey FE, Turse EP, Daglilar E, et al. The dirty aspects of fecal microbiota transplantation: a review of its adverse effects and complications. Curr Opin Pharmacol. 2019;49:29\u201333. https:\/\/doi.org\/10.1016\/j.coph.2019.04.008. [published Online First: 20190516].","journal-title":"Curr Opin Pharmacol"},{"issue":"12","key":"14057_CR16","doi-asserted-by":"publisher","first-page":"3274","DOI":"10.3390\/biomedicines11123274","volume":"11","author":"A Li","year":"2023","unstructured":"Li A, Bowen JM, Ball IA, et al. Autologous faecal microbiota transplantation to improve outcomes of Haematopoietic stem cell transplantation: results of a Single-Centre feasibility study. Biomedicines. 2023;11(12):3274.","journal-title":"Biomedicines"},{"issue":"3","key":"14057_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/jgh3.12874","volume":"7","author":"EC Tucker","year":"2023","unstructured":"Tucker EC, Haylock-Jacobs S, Rapaic M, et al. Stool donor screening within a therapeutic goods administration compliant donor screening program for fecal microbiota transplantation. JGH Open. 2023;7(3):172\u201377. https:\/\/doi.org\/10.1002\/jgh3.12874. [published Online First: 20230221].","journal-title":"JGH Open"},{"issue":"2","key":"14057_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","volume":"42","author":"PA Harris","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010. [published Online First: 20080930].","journal-title":"J Biomed Inf"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14057-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14057-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14057-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T08:11:50Z","timestamp":1744272710000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14057-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14057"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14057-4","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"19 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been designed to comply with the Declaration of Helsinki, the ICH guidelines for Good Clinical Practice and NHMRC National Statement on Ethical Conduct in Research Involving Humans (2007, updated 2018). Ethics approval was obtained from the Human Research Ethics Committee of the Central Adelaide Local Health Network (CALHN), reference number: 2023\/HRE00268. Written informed consent to participate in the study will be obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr Samuel Costello and Dr Sarah Haylock-Jacobs are employees of BiomeBank and Dr Robert Bryant and Dr Samuel Costello are shareholders in BiomeBank.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"656"}}